Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

Université Laval

$1,025,100.00

Deciphering the role of MEF2 transcription factors in testis development and male sex differentiation

FY 2024-25

Summary
We are studying the role of a family of transcription factors (proteins that participate in turning genes on or off), called MEF2. MEF2 factors were first discovered for their essential role in regulating the development of the heart. MEF2 factors are also prominently expressed in the testis but not in the ovary. In the testis, MEF2 factors are found in Sertoli and Leydig cells throughout fetal and post-natal life. Our previous work using Sertoli and Leydig cell lines in culture revealed that MEF2 factors regulate the expression of several genes important for the function of these cells. In addition, MEF2 gene mutations are known to affect human health and some MEF2 mutations have been associated with disrupted testicular development and function in men. The objective of our research is to define the mechanism of action of MEF2 factors (i.e., how they accomplish their functions) in Sertoli and Leydig cell development and function using different mouse models where the Mef2 genes are rendered non-functional exclusively in Leydig cells, and exclusively in Sertoli cells. Understanding the role of MEF2 factors in testis formation and function is essential not only for establishing male/female sex differences during pregnancy and at puberty but also the maintenance of fertility in adulthood. Our research will hopefully lead to better diagnosis of several human pathologies associated with defective Sertoli and/or Leydig cells.
Program
Project Grant
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
522798
Name
Tremblay Jacques J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Biomedical
Prcname2
Clinical Investigation - A: Reproduction, Maternal, Child and Youth Health 2
Projecttitle
Deciphering the role of MEF2 transcription factors in testis development and male sex differentiation
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$1,025,100
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Cell Differentiation; Fertility; Gene Expression; Gene Knockout In Mice; Leydig Cells; Male Sex Differentiation; Puberty; Sertoli Cells; Testis Formation; Transcription Factors
Abstract
We are studying the role of a family of transcription factors (proteins that participate in turning genes on or off), called MEF2. MEF2 factors were first discovered for their essential role in regulating the development of the heart. MEF2 factors are also prominently expressed in the testis but not in the ovary. In the testis, MEF2 factors are found in Sertoli and Leydig cells throughout fetal and post-natal life. Our previous work using Sertoli and Leydig cell lines in culture revealed that MEF2 factors regulate the expression of several genes important for the function of these cells. In addition, MEF2 gene mutations are known to affect human health and some MEF2 mutations have been associated with disrupted testicular development and function in men. The objective of our research is to define the mechanism of action of MEF2 factors (i.e., how they accomplish their functions) in Sertoli and Leydig cell development and function using different mouse models where the Mef2 genes are rendered non-functional exclusively in Leydig cells, and exclusively in Sertoli cells. Understanding the role of MEF2 factors in testis formation and function is essential not only for establishing male/female sex differences during pregnancy and at puberty but also the maintenance of fertility in adulthood. Our research will hopefully lead to better diagnosis of several human pathologies associated with defective Sertoli and/or Leydig cells.
Competitiondate
202503
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Tremblay, Jacques J
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,025,100~ $0~